论文部分内容阅读
目的:观察依达拉奉治疗急性脑梗死的临床疗效。方法:80例急性脑梗死患者随机分为治疗组40例和对照组40例,对照组使用常规的应用抗血小板凝集、改善微循环和对症等治疗,治疗组在对照组的基础上加用依达拉奉注射液30mg+0.9%氯化钠注射液100ml,静脉滴注,每天2次,共用14天。治疗前后定期对患者进行欧洲卒中评分(ESS)及日常生活能力(ADL)的评定。结果:各组治疗后10天ESS及ADL评分差异有显著性,治疗组在两方面均优于对照组(P<0.05),14天后治疗组在显效率及有效率方面明显高于对照组(P<0.05);且无明显不良反应。结论:依达拉奉治疗急性脑梗死安全、有效。
Objective: To observe the clinical efficacy of edaravone in the treatment of acute cerebral infarction. Methods: A total of 80 patients with acute cerebral infarction were randomly divided into treatment group (40 cases) and control group (40 cases). The control group was treated with conventional antiplatelet therapy, microcirculation and symptomatic treatment. The treatment group was treated on the basis of control group Da Lavander injection 30mg + 0.9% sodium chloride injection 100ml, intravenous infusion, 2 times a day for 14 days. Patients were regularly assessed for European Stroke Scale (ESS) and daily living ability (ADL) before and after treatment. Results: The differences of ESS and ADL scores between the two groups were significant at 10 days after treatment. The treatment group was better than the control group in both aspects (P <0.05). After 14 days, the effective rate and effective rate of the treatment group were significantly higher than that of the control group P <0.05); And no obvious adverse reactions. Conclusion: Edaravone is safe and effective in treating acute cerebral infarction.